The findings, published in JAMA Health Forum, reveal a continuing and worrying trend in worsening US mortality compared to other wealthy nations over the last four decades. While excess deaths per year peaked at the height of the COVID-19 pandemic in 2021, excess deaths in 2023 still far exceeded prepandemic levels in 2019 and closely matched the rising pre-pandemic trend. After rising steadily since 1980, excess US deaths reached 1,098,808 in 2021, before dropping to 820,396 in 2022 and 705,331 in 2023, after the acute phase of the pandemic. However, the 2023 figure was still tens of thousands of deaths higher than the 2019 total of 631,247 missing Americans.

An interdisciplinary research team involving the German Center for Infection Research (DZIF) has identified two antiviral drug candidates effective against a wide range of viruses. The study demonstrates how combining computer-aided modeling with laboratory validation can speed up the development of new antiviral drugs. The researchers used computer simulations to search for specific metabolic processes necessary for viral reproduction but not vital for the cell itself. Using this method, the team identified two active agents that successfully combated various viruses in initial laboratory tests. These findings are an important step toward creating drugs that could quickly be made available in the event of a future pandemic. The study was recently published in the journal Communications Biology.

Acute coronary syndrome (ACS) in patients with SARS-CoV-2 infection is primarily driven by inflammation-induced myocardial injury through both direct and indirect mechanisms. Effective clinical management requires a dual approach: addressing cardiovascular lesions while also mitigating virus-induced local and systemic inflammation. This comprehensive approach is essential for improving the diagnosis and treatment of SARS-CoV-2-associated ACS. Emerging evidence highlights the potential of myocardial protective agents, including angiotensin-converting enzyme 2-modulating drugs and traditional Chinese medicine, which not only stabilize plaques and improve endothelial function but also confer cardioprotective effects. Furthermore, advancements in nanotechnology offer promising strategies for targeted therapy—particularly through angiotensin-converting enzyme 2 receptor modulation—by enhancing the precision and efficacy of herbal medicine delivery. This review explores the complex interplay between SARS-CoV-2 infection and ACS pathogenesis, and evaluates the therapeutic potential of pharmacological, herbal, and nanotechnology-based interventions in managing this multifaceted condition.

A National Institutes of Health (NIH)-funded study by researchers from Johns Hopkins Medicine, the Johns Hopkins Bloomberg School of Public Health and The Johns Hopkins University Whiting School of Engineering finds that neutrophils — the most abundant type of white blood cells in humans — may be altered by SARS-CoV-2, the virus that causes COVID-19, to cease their normal function of destroying pathogens in the body and, instead, significantly inhibit other immune cells critical for fighting the virus. 

New insights into the complexities of Long COVID have been brought to light, thanks to an international collaborative effort with the participation of researchers from GCAT|Genomes for life, a strategic project of IGTP. A study published today in Nature Genetics used the vast data from the COVID-19 Host Genetics Initiative to perform the first study examining the entire genetic code specifically focused on Long COVID.

A research group led by Professor Takahiro Nemoto from the Department of Psychiatry and Neuroscience and the Department of Social Implementation Psychiatry at the Toho University Faculty of Medicine analyzed large-scale clinical data to examine the association between the COVID-19 pandemic and the incidence of anorexia nervosa (ICD-10 classification: F50.0) in young patients in Japan. Their study revealed that the number of patients with anorexia nervosa increased after the onset of the COVID-19 pandemic. This research was published in the international academic journal Medicina (Lithuania) on March 3, 2025.

The rapid evolution of SARS-CoV-2 variants during the COVID-19 pandemic emphasized the need for advanced tools to predict future outbreaks. The study introduces CoVFit, an AI-driven model that analyzes spike protein mutations to assess the fitness of SARS-CoV-2 variants. By combining molecular and epidemiological data, CoVFit provides early insights into the transmissibility and immunity evasion of emerging variants, offering a powerful tool for pandemic preparedness, vaccine design, and global risk assessment.

Hydrogen boride (HB) nanosheets can inactivate viruses, bacteria, and fungi within minutes in the dark conditions. By coating surfaces with HB nanosheets, it rapidly inactivates SARS-CoV-2, influenza virus, and other pathogens. The nanosheets work by denaturing microbial proteins, offering a safe, effective, and versatile antimicrobial coating for everyday items.